{"nctId":"NCT00651040","briefTitle":"Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM","startDateStruct":{"date":"2008-05"},"conditions":["Polymyositis","Dermatomyositis"],"count":31,"armGroups":[{"label":"Prednison","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Prednisone"]},{"label":"Prednison + methotrexate","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Prednisone","Drug: Methotrexate"]}],"interventions":[{"name":"Prednisone","otherNames":["Prednisolone"]},{"name":"Methotrexate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age between 18 - 80 years.\n2. Patients with definite or probable polymyositis or dermatomyositis diagnosed according to diagnostic criteria (9, 10) (Appendix 1)\n3. Physician's own judgment of the disease activity that requires high dose immunosuppressive treatment (based on clinical assessment of weakness, elevation of muscle enzymes and, if available, on magnetic resonance imaging findings).\n4. Previously untreated patients with the exception of glucocorticoid treatment up to 8 weeks\n5. Signed informed consent.\n\nExclusion Criteria:\n\n1. Treatment with any immunosuppressive drug prior the study start.\n2. Treatment with glucocorticoids (\\> 20 mg of Prednisone or equivalent) more than 8 weeks prior to study start.\n3. Drug induced myositis.\n4. Polymyositis and dermatomyositis in association with other connective tissue disease.\n5. Inclusion body myositis.\n6. Patients with immunodeficiency syndrome.\n7. Pregnancy and lactation.\n8. Fertile women not using adequate contraception during the study, women planning to have children during the study course or 12 months after the end of the study.\n9. Malignancy.\n10. Juvenile dermatomyositis.\n11. Uncontrolled, clinically significant hematological, cardiovascular, pulmonary, endocrine, metabolic, gastrointestinal, hepatic or renal disease, which according to physician's consideration would interfere with high dose glucocorticoid and immunosuppressive treatment or would prevent to follow the treatment protocol.\n12. Severe infection.\n13. History of drug or alcohol abuse within the previous 6 months.\n14. Patients known to be HIV positive.\n15. Known hypersensitivity to methotrexate.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Primary Endpoint is the Total Dose of Glucocorticoids Administered Between Baseline and the End of Treatment.","description":"The primary endpoint which has benn measured was the total dose of glucocorticoids administered between baseline and the end of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":"65.7"},{"groupId":"OG001","value":"135","spread":"45.2"}]}]}]},{"type":"SECONDARY","title":"Assessment of Disease Activity and Damage,Muscle Strength and Endurance, Enzyme Levels, Glucocorticoid Side-effects, Dose, HAQ,SF-36, Treatment Failures","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":16},"commonTop":["infection","Musculoskeletal","general","gastrointestinal","cardiovascular"]}}}